Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate effect on thrombosis-forming ability in dyslipidemia with coronary artery disease history
jRCTs071210130Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in dyslipidemia and coronary arteriosclerosis (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in plasma fibrinogen (FAS). Started Apr 2022; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemiacoronary arteriosclerosis
Beyond the preview
Go deeper on jRCTs071210130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210130.